Dyadic International (NASDAQ:DYAI) Stock Price Crosses Above 50 Day Moving Average – Time to Sell?

Dyadic International Inc. (NASDAQ:DYAI) shares passed above its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $0.81 and traded as high as $1.34. Dyadic International shares last traded at $1.21, with a volume of 770,602 shares traded.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Dyadic International in a research note on Wednesday, June 24th. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $3.00.

Dyadic International Trading Down 2.5%

The company has a debt-to-equity ratio of 4.08, a quick ratio of 2.42 and a current ratio of 2.42. The firm has a 50 day simple moving average of $0.82 and a two-hundred day simple moving average of $0.84. The firm has a market capitalization of $43.36 million, a P/E ratio of -5.17 and a beta of 1.15.

Dyadic International (NASDAQ:DYAI) last posted its earnings results on Wednesday, May 13th. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.01). The firm had revenue of $1.11 million during the quarter, compared to the consensus estimate of $0.90 million. Dyadic International had a negative return on equity of 1,005.45% and a negative net margin of 192.40%. Equities research analysts forecast that Dyadic International Inc. will post 0.13 earnings per share for the current year.

Institutional Investors Weigh In On Dyadic International

Several institutional investors and hedge funds have recently added to or reduced their stakes in DYAI. Landscape Capital Management L.L.C. purchased a new position in shares of Dyadic International in the 3rd quarter worth approximately $190,000. Marathon Capital Management increased its position in shares of Dyadic International by 142.9% during the fourth quarter. Marathon Capital Management now owns 85,000 shares of the biotechnology company’s stock valued at $80,000 after acquiring an additional 50,000 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Dyadic International by 13.7% during the fourth quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock valued at $284,000 after acquiring an additional 36,266 shares during the last quarter. Finally, Bank of America Corp DE lifted its holdings in Dyadic International by 16,146.7% during the fourth quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock worth $47,000 after acquiring an additional 26,965 shares during the period. Hedge funds and other institutional investors own 27.95% of the company’s stock.

Dyadic International Company Profile

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.